Trial Profile
A long-term phase III study of HOB-294 in patients with overactive bladder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 01 Jun 2016 New trial record